Работы, цитирующие эту работу

Работ: 4

Работа: CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

1. CAR-T cell combination therapy: the next revolution in cancer treatment

   Maysoon Al‐Haideri, Santalia Banne Tondok, Salar Hozhabri Safa +8

   Обзорная статьяCAR-T cell therapy researchCancer Cell International2022Цитирований: 2

   ABIABI:AkademIndex/openalex/2022.review-article.000004

2. Genetic engineering in oncology based on CRISPR-Cas9 technology

   D. Polatova, А. Yu. Madaminov, А. V. Savkin +1

   СтатьяCRISPR and Genetic EngineeringSiberian Journal of Oncology2024Цитирований: 0

   ABIABI:AkademIndex/openalex/2024.article.008036

3. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

   Manh-Cuong Vo, Van-Dinh-Huan Tran, Van‐Tan Nguyen +5

   СтатьяCAR-T cell therapy researchJournal of Hematology & Oncology2025Цитирований: 0

   ABIABI:AkademIndex/openalex/2025.article.000083

4. Epigenetic mechanisms and next-gen editing platforms in hematology: From molecular basis to therapeutic frontiers

   Minzhi Huang, Ahmad Ewadi, Nazli Servatian +6

   Обзорная статьяCRISPR and Genetic EngineeringCritical Reviews in Oncology/Hematology2025Цитирований: 0

   ABIABI:AkademIndex/openalex/2025.review-article.000099